>Mercado de vacunas en Oriente Medio y África, por composición (vacunas combinadas, monovacunas), tipo (vacunas de subunidades, recombinantes, polisacáridas y conjugadas, vacunas vivas atenuadas, vacunas inactivadas, vacunas toxoides, vacunas de ADN), tipo (vacuna de rutina, vacuna recomendada, vacuna requerida), edad de administración (vacuna pediátrica, vacuna para adultos), enfermedades (enfermedad neumocócica, sarampión, paperas y varicela, DPT, hepatitis, influenza, fiebre tifoidea, meningococo, rabia, encefalitis japonesa, fiebre amarilla, otras), vía de administración (inyectable, oral, nasal), usuario final (hospitales comunitarios, hospitales, centros especializados, clínicas, otros), canal de distribución (farmacia hospitalaria, farmacia minorista, farmacia en línea), país (Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Kuwait, Egipto, Resto de Oriente Medio y África: tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado: mercado de vacunas en Oriente Medio y África
Se espera que el mercado de vacunas gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 5,8% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 1.459,40 millones para 2028. La alta prevalencia de enfermedades crónicas como la gripe y las enfermedades infecciosas bacterianas y la presencia de productos en desarrollo son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico.
Las vacunas son productos que tienen la capacidad de reducir el riesgo de contraer una enfermedad al trabajar con el sistema inmunológico del cuerpo para desarrollar la protección contra los patógenos mortales. Se han descubierto varios tipos de vacunas para enfermedades potencialmente mortales que previenen alrededor de 2 a 3 millones de muertes cada año causadas por enfermedades como el tétanos, la difteria , la tos ferina, el sarampión y la gripe, entre otras.
El lanzamiento de una vacuna nueva y novedosa genera la confianza de los pacientes y ofrece al mercado un nuevo futuro que puede tener un efecto positivo en el crecimiento del mercado de vacunas. Además, el lanzamiento de una nueva vacuna también muestra que los actores del mercado participan constantemente en el crecimiento del mercado de vacunas. Esto significa que la introducción de productos innovadores actúa como motor del crecimiento del mercado de vacunas. Los procesos de regulación y la formación de documentos de las empresas de fabricación en diferentes países pueden obstaculizar el crecimiento del mercado de vacunas. Los actores del mercado que operan en el mercado de vacunas están adoptando varias iniciativas estratégicas que se espera que brinden oportunidades para sus negocios en varias dimensiones y lideren el crecimiento del mercado de vacunas. El miedo entre los pacientes relacionado con las inyecciones y los pinchazos con agujas actúa como un desafío para el crecimiento del mercado de vacunas.
The vaccines market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the vaccines market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa Vaccines Market Scope and Market Size
The vaccines market is segmented on the basis of composition, type, kind, age of administration, diseases, route of administration, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of composition, the vaccines market is segmented into combination vaccines, monovaccines. In 2021, combination vaccines segment is dominating the market because combination vaccines are effective against multiple diseases by administration of a single shot.
- On the basis of type, the vaccines market is segmented into subunit, recombinant, polysaccharide and conjugate vaccines, live-attenuated vaccines, inactivated vaccines, toxoid vaccines and DNA vaccines. In 2021, subunit, recombinant, polysaccharide and conjugate vaccine segment is dominating the market because these vaccines have been reported to induce strong immune response on almost everyone who needs them including people with weakened immune systems and long-term health problems.
- On the basis of kind, the vaccines market is segmented into routine vaccine, recommended vaccine and required vaccine. In 2021, routine vaccine segment is dominating the market because these are mostly used for childhood vaccination and government is putting major emphasis on childhood vaccination all over the world.
- On the basis of age of administration, the vaccines market is segmented into pediatric vaccine and adult vaccine. In 2021, pediatric vaccine segment is dominating the market because children are more prone to infectious disease among other due to developing immune system and hence needs proper vaccination.
- On the basis of diseases, the vaccines market is segmented into pneumococcal disease, measles, mumps & varicella, DPT, hepatitis, influenza, typhoid, meningococcal, rabies, Japanese encephalitis, yellow fever and others. In 2021, pneumococcal disease segment is dominating the market because of rising prevalence on pneumonia infection and increasing immunization campaign launch for the betterment of the population.
- Según la vía de administración, el mercado de vacunas se segmenta en inyectables , orales y nasales. En 2021, el segmento inyectable domina el mercado porque la mayoría de las vacunas se administran por vía parenteral e inducen una fuerte respuesta sistémica cuando se inyectan por la misma vía.
- En función del usuario final, el mercado de vacunas se segmenta en hospitales comunitarios, hospitales , centros especializados, clínicas y otros. En 2021, el segmento de hospitales comunitarios domina el mercado porque la mayor parte de la vacunación e inmunización la llevan a cabo los organismos reguladores y las autoridades competentes.
- Según el canal de distribución, el mercado de vacunas se segmenta en farmacias hospitalarias, farmacias minoristas y farmacias en línea. En 2021, el segmento de farmacias hospitalarias domina el mercado porque las vacunas se adquieren directamente de los distribuidores de la empresa.
Análisis del mercado de vacunas a nivel de país
Se analiza el mercado de vacunas y se proporciona información sobre el tamaño del mercado en función de la composición, el tipo, la clase, la edad de administración, las enfermedades, la vía de administración, el usuario final y el canal de distribución como se mencionó anteriormente.
Los países cubiertos en el informe del mercado de vacunas son Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Kuwait, Egipto, el resto de Medio Oriente y África.
Se espera que el segmento inyectable en la región de Medio Oriente y África crezca con la tasa de crecimiento más alta en el período de pronóstico de 2021 a 2028 porque las formulaciones inyectables brindan una acción duradera de manera sostenida. Arabia Saudita lidera el crecimiento del mercado de Medio Oriente y África y el segmento inyectable domina en este país debido al aumento en la prevalencia de infecciones relacionadas con la gripe que se relacionan con la inmunidad a largo plazo.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de Medio Oriente y África y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.
La creciente conciencia sobre la vacunación y el lanzamiento de nuevas vacunas están impulsando el crecimiento del mercado de las vacunas
El mercado de vacunas también le proporciona un análisis detallado del mercado para el crecimiento de cada país en la industria de vacunas con las ventas de medicamentos de vacunas, el impacto del avance en la tecnología de vacunas y los cambios en los escenarios regulatorios con su apoyo al mercado de vacunas. Los datos están disponibles para el período histórico de 2010 a 2019.
Análisis del panorama competitivo y de la cuota de mercado de las vacunas
El panorama competitivo del mercado de vacunas proporciona detalles por competidor. Los detalles incluidos son la descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, los procesos de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y la variedad de productos, el dominio de las aplicaciones y la curva de supervivencia de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado de vacunas.
Las principales empresas que comercializan vacunas son Valneva SE, Takeda Pharmaceutical Company Limited, Abbott, AstraZeneca, Sanofi, Pfizer Inc., Janssen Global Services, LLC (una subsidiaria de Johnson & Johnson Services, Inc.), F. Hoffmann-La Roche Ltd, Panacea Biotec Ltd, GlaxoSmithKline plc, entre otros actores nacionales e internacionales. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Muchos lanzamientos y acuerdos de productos también son iniciados por empresas de todo el mundo, lo que también está acelerando el mercado de las vacunas.
Por ejemplo,
- En febrero de 2020, Abbott lanzó una nueva vacuna tetravalente y de subunidades. La vacuna se lanzó con la capacidad de brindar protección contra cuatro cepas virales de influenza. El producto lanzado impulsó la cartera de productos de la empresa y le permitió generar más ingresos.
- En julio de 2018, Sanofi lanzó la vacuna FluQuadri en India, que brinda una mejor protección contra las cuatro cepas de las vacunas contra la influenza. Como la mayoría de las vacunas disponibles contra la influenza son de tipo trivalente, el lanzamiento de este producto ayudó a la empresa a expandir su presencia en el mercado de las vacunas y a obtener un crecimiento lucrativo en el mercado.
La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de vacunas, lo que también brinda el beneficio a las organizaciones de mejorar su oferta de vacunas.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA VACCINES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 COMPOSITION LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 MIDDLE EAST & AFRICA VACCINES MARKET: LAWS AND REGULATIONS
8 MIDDLE EAST & AFRICA VACCINES MARKET: LOGISTICS OF VACCINES
8.1 COLD CHAIN STORAGE:
8.2 REGULATIONS ASSOCIATED WITH VACCINE SUPPLY
8.3 PROCESS OF LOGISTICS
8.4 CHALLENGES IN LOGISTICS
8.5 CHALLENGES FACED BY INDIA FOR UPCOMING COVID 19 VACCINE:
8.6 CHALLENGES FACED BY LATIN AMERICA FOR UPCOMING VACCINE:
8.7 CHALLENGES FACED BY NIGERIA FOR VACCINE LOGISTICS:
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS
9.1.2 HIGH PREVALENCE OF CHRONIC CONDITION SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES
9.1.3 IMPROVEMENT IN TREATMENT
9.1.4 LAUNCH OF NEWER VACCINES
9.1.5 INCREASING GOVERNMENT SUPPORT
9.2 RESTRAINTS
9.2.1 UNAVAILABILITY OF REGISTERED VACCINES
9.2.2 HIGH COST AND DIFFERENCES IN PRICING OF THE VACCINES
9.2.3 DIFFICULTIES ASSOCIATED WITH TRANSPORT AND PRODUCTION OF VACCINES
9.3 OPPORTUNITIES
9.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
9.3.2 PRESENCE OF PIPELINE PRODUCTS
9.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
9.3.4 INCREASING AWARENESS FOR VACCINATION
9.4 CHALLENGES
9.4.1 SIDE EFFECTS CAUSED BY VACCINES
9.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS
9.4.3 PRODUCT RECALL
10 IMPACT OF COVID-19 ON MIDDLE EAST & AFRICA VACCINES MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON SUPPLY CHAIN
10.3 IMPACT ON DEMAND
10.4 CONCLUSION
11 MIDDLE EAST & AFRICA VACCINES MARKET, BY COMPOSITION
11.1 OVERVIEW
11.2 COMBINATION VACCINES
11.3 MONO VACCINES
12 MIDDLE EAST & AFRICA VACCINES MARKET, BY TYPE
12.1 OVERVIEW
12.2 SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES
12.2.1 PNEUMOCOCCAL DISEASE
12.2.2 HIB (HAEMOPHILUS INFLUENZAE TYPE B) DISEASE
12.2.3 HPV (HUMAN PAPILLOMA VIRUS)
12.2.4 HEPATITIS B
12.2.5 MENINGOCOCCAL
12.2.6 SHINGLES
12.2.7 WHOOPING COUGH
12.2.8 OTHERS
12.3 LIVE-ATTENUTAED VACCINES
12.3.1 ROTAVIRUS
12.3.2 MEASLES
12.3.3 MUMPS
12.3.4 RUBELLA
12.3.5 SMALLPOX
12.3.6 YELLOW FEVER
12.3.7 OTHERS
12.4 INACTIVATED VACCINES
12.4.1 FLU (SHOT ONLY)
12.4.2 POLIO (SHOT ONLY)
12.4.3 HEPATITIS A
12.4.4 RABIES
12.4.5 OTHERS
12.5 TOXOID VACCINES
12.5.1 DIPHTHERIA, TETANUS & PERTUSSIS (DTP)
12.5.2 OTHERS
12.6 DNA VACCINES
13 MIDDLE EAST & AFRICA VACCINES MARKET, BY KIND
13.1 OVERVIEW
13.2 ROUTINE VACCINE
13.2.1 PNEUMOCOCCAL
13.2.2 DIPHTHERIA
13.2.3 HIB (HAEMOPHILUS INFLUENZAE TYPE B) DISEASE
13.2.4 MEASLES
13.2.5 MUMPS
13.2.6 HEPATITIS B
13.2.7 RUBELLA
13.2.8 POLIO
13.2.9 OTHERS
13.3 RECOMMENDED VACCINES
13.3.1 TYPHOID FEVER VACCINES
13.3.2 HEPATITIS A
13.3.3 RABIES
13.3.4 JAPANESE ENCEPHALITIS
13.3.5 TICK-BORNE ENCEPHALITIS
13.3.6 CHOLERA
13.3.7 OTHERS
13.4 REQUIRED VACCINES
13.4.1 MENINGOCOCCAL
13.4.2 YELLOW FEVER
13.4.3 OTHERS
14 MIDDLE EAST & AFRICA VACCINES MARKET, BY AGE OF ADMINISTRATION
14.1 OVERVIEW
14.2 PEDIATRIC VACCINES
14.2.1 PNEUMOCOCCAL
14.2.2 MEASLES, MUMPS, AND, RUBELLA
14.2.3 DIPHTHERIA, TETANUS & PERTUSIS (DPT)
14.2.4 ROTAVIRUS
14.2.5 MENINGOCOCCAL
14.2.6 VARICELLA
14.2.7 POLIO
14.2.8 TUBERCULOSIS
14.2.9 MALARIA
14.2.10 OTHERS
14.3 ADULT VACCINES
14.3.1 INLFUENZA
14.3.2 HPV (HUMAN PAPILLOMA VIRUS)
14.3.3 TYPHOID
14.3.4 HEPATITIS B
14.3.5 JAPANESE ENCEPHALITIS
14.3.6 YELLOW FEVER
14.3.7 HIV
14.3.8 CANCER
14.3.9 OTHERS
15 MIDDLE EAST & AFRICA VACCINES MARKET, BY DISEASES
15.1 OVERVIEW
15.2 PNEUMOCCOCAL DISEASE
15.3 MEASLES, MUMPS & RUBELLA
15.4 DPT
15.5 HEPATITIS
15.6 INFLUENZA
15.7 TYPHOID
15.8 MENINGOCOCCAL
15.9 VARICELLA
15.1 RABIES
15.11 JAPANESE ENCEPHALITIS
15.12 YELLOW FEVER
15.13 OTHERS
16 MIDDLE EAST & AFRICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION
16.1 OVERVIEW
16.2 INJECTABLE
16.2.1 INTRAMUSCULAR
16.2.2 SUBCUTANEOUS
16.2.3 INTRADERMAL
16.3 ORAL
16.4 NASAL
17 MIDDLE EAST & AFRICA VACCINES MARKET, BY END USER
17.1 OVERVIEW
17.2 COMMUNITY HOSPITALS
17.3 HOSPITALS
17.4 SPECIALTY CENTRES
17.5 CLINICS
17.6 OTHERS
18 MIDDLE EAST & AFRICA VACCINES MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.4 ONLINE PHARMACY
19 MIDDLE EAST & AFRICA VACCINES MARKET, BY GEOGRAPHY
19.1 MIDDLE EAST & AFRICA
19.1.1 SAUDI ARABIA
19.1.1.1 JORDAN
19.1.1.2 OMAN
19.1.1.3 QATAR
19.1.1.4 YEMEN
19.1.1.5 REST OF SAUDI ARABIA
19.1.2 SOUTH AFRICA
19.1.3 UAE
19.1.4 ISRAEL
19.1.5 KUWAIT
19.1.6 EGYPT
19.1.7 REST OF MIDDLE EAST & AFRICA
20 MIDDLE EAST & AFRICA VACCINES MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
21 COMPANY PROFILE
21.1 GLAXOSMITHKLINE PLC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.1.6 SWOT ANALYSIS
21.2 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.2.6 SWOT ANALYS
21.3 SANOFI
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.3.6 SWOT ANALYS
21.4 PFIZER INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.4.6 SWOT ANAL
21.5 ABBOTT
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 ALK
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENTS
21.7 ALTIMMUNE
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 ASTRAZENECA
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENTS
21.9 BAVARIAN NORDIC
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENTS
21.1 BAXTER VACCINES (A SUBSIDIARY OF BAXTER)
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 BHARAT BIOTECH
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENTS
21.12 BIO FARMA
21.12.1 COMPANY SNAPSHOT
21.12.2 PRODUCT PORTFOLIO
21.12.3 RECENT DEVELOPMENTS
21.13 BIOLOGICAL E LIMITED
21.13.1 COMPANY SNAPSHOT
21.13.2 PRODUCT PORTFOLIO
21.13.3 RECENT DEVELOPMENTS
21.14 DAIICHI SANKYO COMPANY, LIMITED
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 DYNAVAX TECHNOLOGIES
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 EMERGENT BIOSOLUTIONS INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 F. HOFFMANN-LA ROCHE LTD
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENT
21.18 JANSSEN MIDDLE EAST & AFRICA SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 LANZHOU BIOLOGICAL PRODUCTS RESEARCH INSTITUTE CO., LTD.,
21.19.1 COMPANY SNAPSHOT
21.19.2 PRODUCT PORTFOLIO
21.19.3 RECENT DEVELOPMENTS
21.2 PANACEA BIOTEC LTD
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 SEQIRUS (A SUBSIDIARY OF CSL LIMITED)
21.21.1 COMPANY SNAPSHOT
21.21.2 REVENUE ANALYSIS
21.21.3 PRODUCT PORTFOLIO
21.21.4 RECENT DEVELOPMENTS
21.21.5 SWOT ANALYSIS
21.22 SERUM INSTITUTE OF INDIA PVT. LTD.
21.22.1 COMPANY SNAPSHOT
21.22.2 PRODUCT PORTFOLIO
21.22.3 RECENT DEVELOPMENTS
21.23 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.23.1 COMPANY SNAPSHOT
21.23.2 REVENUE ANALYSIS
21.23.3 PRODUCT PORTFOLIO
21.23.4 RECENT DEVELOPMENTS
21.24 VALNEVA SE
21.24.1 COMPANY SNAPSHOT
21.24.2 REVENUE ANALYSIS
21.24.3 PRODUCT PORTFOLIO
21.24.4 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 MIDDLE EAST & AFRICA VACCINES MARKET, PIPELINE ANALYSIS
TABLE 2 REGULATIONS IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS
TABLE 3 RECOMMENDED TEMPERATURE AND STORAGE LENGTH AT VARIOUS LEVEL OF THE COLD CHAIN.
TABLE 4 PROCEDURES FOR REPORTING TO UNICEF VACCINE ARRIVALS.
TABLE 5 LOGISITCS PROCESS ACORSS DIFFERENT REGIONS.
TABLE 6 THE U.S. FUNDING FOR GAVI (2015-2019)
TABLE 7 PRICE OF THE VACCINES BETWEEN THE U.S. AND DEVELOPING COUNTRIES
TABLE 8 VACCINES UNDER CLINICAL TRIAL
TABLE 9 THE SIDE EFFECTS RELATED TO THE VACCINES
TABLE 10 INCREASE IN OPERATIONAL COST COMPONENTS DUE TO COVID-19
TABLE 11 TOTAL NUMBER OF CASES FOR MEASLES REPORTED BY THE TEN COUNTRIES
TABLE 12 MIDDLE EAST & AFRICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA COMBINATION VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA MONO VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA INACTIVATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA TOXOID VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA ROUTINE VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA RECOMMENDED VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA REQUIRED VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA PEDIATRIC VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA ADULT VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA PNEUMOCOCCAL DISEASE IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA MEASLES, MUMPS & RUBELLA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA DPT IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA HEPATITIS IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA INFLUENZA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA TYPHOID IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA MENINGOCOCCAL IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA VARICELLA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA RABIES IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA JAPANESE ENCEPHALITIS IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA YELLOW FEVER IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA OTHER IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA INJECTABLE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA ORAL IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA NASAL IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA COMMUNITY HOSPITALS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA HOSPITALS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA SPECIALTY CENTRES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA CLINICS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA OTHERS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA RETAIL PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA ONLINE PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA VACCINES MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 MIDDLE EAST & AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 MIDDLE EAST & AFRICA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 MIDDLE EAST & AFRICA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 MIDDLE EAST & AFRICA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 70 MIDDLE EAST & AFRICA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 71 MIDDLE EAST & AFRICA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 72 MIDDLE EAST & AFRICA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 73 MIDDLE EAST & AFRICA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 74 MIDDLE EAST & AFRICA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 75 MIDDLE EAST & AFRICA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 76 MIDDLE EAST & AFRICA VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 77 MIDDLE EAST & AFRICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 MIDDLE EAST & AFRICA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 79 MIDDLE EAST & AFRICA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 80 MIDDLE EAST & AFRICA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 92 SAUDI ARABIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 94 SAUDI ARABIA VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 95 SAUDI ARABIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 SAUDI ARABIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 SAUDI ARABIA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 98 SAUDI ARABIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 99 JORDAN VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 100 JORDAN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 101 JORDAN SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 JORDAN LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 JORDAN INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 JORDAN TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 JORDAN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 106 JORDAN ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 107 JORDAN RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 108 JORDAN REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 109 JORDAN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 JORDAN PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 111 JORDAN ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 112 JORDAN VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 113 JORDAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 114 JORDAN INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 115 JORDAN VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 116 JORDAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 117 OMAN VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 118 OMAN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 119 OMAN SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 120 OMAN LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 OMAN INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 OMAN TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 OMAN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 124 OMAN ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 125 OMAN RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 126 OMAN REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 127 OMAN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 128 OMAN PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 129 OMAN ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 130 OMAN VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 131 OMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 132 OMAN INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 133 OMAN VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 134 OMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 135 QATAR VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 136 QATAR VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 QATAR SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 QATAR LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 139 QATAR INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 140 QATAR TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 141 QATAR VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 142 QATAR ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 143 QATAR RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 144 QATAR REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 145 QATAR VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 146 QATAR PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 147 QATAR ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 148 QATAR VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 149 QATAR VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 150 QATAR INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 151 QATAR VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 152 QATAR VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 153 YEMEN VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 154 YEMEN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 YEMEN SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 YEMEN LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 YEMEN INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 YEMEN TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 YEMEN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 160 YEMEN ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 161 YEMEN RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 162 YEMEN REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 163 YEMEN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 164 YEMEN PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 165 YEMEN ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 YEMEN VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 167 YEMEN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 168 YEMEN INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 169 YEMEN VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 170 YEMEN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 171 REST OF SAUDI ARABIA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 172 REST OF SAUDI ARABIA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 REST OF SAUDI ARABIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 REST OF SAUDI ARABIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 REST OF SAUDI ARABIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 REST OF SAUDI ARABIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 REST OF SAUDI ARABIA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 178 REST OF SAUDI ARABIA ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 179 REST OF SAUDI ARABIA RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 180 REST OF SAUDI ARABIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 181 REST OF SAUDI ARABIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 182 REST OF SAUDI ARABIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 183 REST OF SAUDI ARABIA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 REST OF SAUDI ARABIA VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 185 REST OF SAUDI ARABIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 186 REST OF SAUDI ARABIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 187 REST OF SAUDI ARABIA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 188 REST OF SAUDI ARABIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 189 SOUTH AFRICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 190 SOUTH AFRICA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 SOUTH AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 SOUTH AFRICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 SOUTH AFRICA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 SOUTH AFRICA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 SOUTH AFRICA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 196 SOUTH AFRICA ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 197 SOUTH AFRICA RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 198 SOUTH AFRICA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 199 SOUTH AFRICA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 200 SOUTH AFRICA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 201 SOUTH AFRICA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 202 SOUTH AFRICA VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 203 SOUTH AFRICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 204 SOUTH AFRICA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 205 SOUTH AFRICA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 206 SOUTH AFRICA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 207 UAE VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 208 UAE VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 209 UAE SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 210 UAE LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 211 UAE INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 212 UAE TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 213 UAE VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 214 UAE ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 215 UAE RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 216 UAE REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 217 UAE VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 218 UAE PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 219 UAE ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 220 UAE VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 221 UAE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 222 UAE INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 223 UAE VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 224 UAE VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 225 ISRAEL VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 226 ISRAEL VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 ISRAEL SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 228 ISRAEL LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 229 ISRAEL INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 230 ISRAEL TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 231 ISRAEL VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 232 ISRAEL ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 233 ISRAEL RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 234 ISRAEL REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 235 ISRAEL VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 236 ISRAEL PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 237 ISRAEL ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 238 ISRAEL VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 239 ISRAEL VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 240 ISRAEL INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 241 ISRAEL VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 242 ISRAEL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 243 KUWAIT VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 244 KUWAIT VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 245 KUWAIT SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 246 KUWAIT LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 247 KUWAIT INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 248 KUWAIT TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 249 KUWAIT VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 250 KUWAIT ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 251 KUWAIT RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 252 KUWAIT REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 253 KUWAIT VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 254 KUWAIT PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 255 KUWAIT ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 256 KUWAIT VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 257 KUWAIT VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 258 KUWAIT INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 259 KUWAIT VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 260 KUWAIT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 261 EGYPT VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 262 EGYPT VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 263 EGYPT SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 264 EGYPT LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 265 EGYPT INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 266 EGYPT TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 267 EGYPT VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 268 EGYPT ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 269 EGYPT RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 270 EGYPT REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 271 EGYPT VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 272 EGYPT PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 273 EGYPT ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 274 EGYPT VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 275 EGYPT VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 276 EGYPT INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 277 EGYPT VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 278 EGYPT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 279 REST OF MIDDLE EAST & AFRICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
Lista de figuras
LIST OF FIGURES
FIGURE 1 MIDDLE EAST & AFRICA VACCINES MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA VACCINES MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA VACCINES MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA VACCINES MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA VACCINES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA VACCINES MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST & AFRICA VACCINES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST & AFRICA VACCINES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA VACCINES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA VACCINES MARKET: SEGMENTATION
FIGURE 11 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS AND HIGH PREVALENCE OF CHRONIC CONDITION SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES ARE DRIVING THE MIDDLE EAST & AFRICA VACCINES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA VACCINES MARKET IN 2021 & 2028
FIGURE 13 FDA REGULATORY REVIEW PROCESS OF VACCINES
FIGURE 14 AEFI ORGANIZATIONAL STRUCTURES
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA VACCINES MARKET
FIGURE 16 MIDDLE EAST & AFRICA VACCINATION COVERAGE IN THE WORLD (2019)
FIGURE 17 PEDIATRIC DEATHS CAUSED BY INFLUENZA IN THE U.S. (2017 – 2020)
FIGURE 18 MIDDLE EAST & AFRICA PREVALENCE OF HBV INFECTION WORLDWIDE IN 2018
FIGURE 19 HEALTHCARE EXPENDITURE PER CAPITA, 2018
FIGURE 20 TOTAL NUMBER OF CASES FOR MEASLES REPORTED BY THE TEN COUNTRIES
FIGURE 21 MIDDLE EAST & AFRICA VACCINES MARKET: BY COMPOSITION, 2021
FIGURE 22 MIDDLE EAST & AFRICA VACCINES MARKET: BY COMPOSITION, 2019-2028 (USD MILLION)
FIGURE 23 MIDDLE EAST & AFRICA VACCINES MARKET: BY COMPOSITION, CAGR (2021-2028)
FIGURE 24 MIDDLE EAST & AFRICA VACCINES MARKET: BY COMPOSITION, LIFELINE CURVE
FIGURE 25 MIDDLE EAST & AFRICA VACCINES MARKET: BY TYPE, 2021
FIGURE 26 MIDDLE EAST & AFRICA VACCINES MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 27 MIDDLE EAST & AFRICA VACCINES MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 28 MIDDLE EAST & AFRICA VACCINES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 29 MIDDLE EAST & AFRICA VACCINES MARKET: BY KIND, 2019
FIGURE 30 MIDDLE EAST & AFRICA VACCINES MARKET: BY KIND, 2019-2028 (USD MILLION)
FIGURE 31 MIDDLE EAST & AFRICA VACCINES MARKET: BY KIND, CAGR (2021-2028)
FIGURE 32 MIDDLE EAST & AFRICA VACCINES MARKET: BY KIND, LIFELINE CURVE
FIGURE 33 MIDDLE EAST & AFRICA VACCINES MARKET: BY AGE OF ADMINISTRATION, 2019
FIGURE 34 MIDDLE EAST & AFRICA VACCINES MARKET: BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 35 MIDDLE EAST & AFRICA VACCINES MARKET: BY AGE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 36 MIDDLE EAST & AFRICA VACCINES MARKET: BY AGE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 37 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISEASES, 2020
FIGURE 38 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISEASES, 2019-2028 (USD MILLION)
FIGURE 39 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISEASES, CAGR (2021-2028)
FIGURE 40 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 41 MIDDLE EAST & AFRICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 42 MIDDLE EAST & AFRICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 43 MIDDLE EAST & AFRICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 44 MIDDLE EAST & AFRICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 45 MIDDLE EAST & AFRICA VACCINES MARKET: BY END USER, 2019
FIGURE 46 MIDDLE EAST & AFRICA VACCINES MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 47 MIDDLE EAST & AFRICA VACCINES MARKET: BY END USER, CAGR (2021-2028)
FIGURE 48 MIDDLE EAST & AFRICA VACCINES MARKET: BY END USER, LIFELINE CURVE
FIGURE 49 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 50 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 51 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 52 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 53 MIDDLE EAST & AFRICA VACCINES MARKET: SNAPSHOT (2020)
FIGURE 54 MIDDLE EAST & AFRICA VACCINES MARKET: BY COUNTRY (2020)
FIGURE 55 MIDDLE EAST & AFRICA VACCINES MARKET: BY COUNTRY (2021 & 2028)
FIGURE 56 MIDDLE EAST & AFRICA VACCINES MARKET: BY COUNTRY (2020 & 2028)
FIGURE 57 MIDDLE EAST & AFRICA VACCINES MARKET: BY TYPE (2021-2028)
FIGURE 58 MIDDLE EAST & AFRICA VACCINES MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
